Contribution of bone marrow-derived cells to the pro-inflammatory effects of protease-activated receptor-2 in colitis by Hyun, Eric et al.
ORIGINAL RESEARCH PAPER
Contribution of bone marrow-derived cells
to the pro-inﬂammatory effects of protease-activated
receptor-2 in colitis
Eric Hyun • Patricia Andrade-Gordon •
Martin Steinhoff • Paul L. Beck • Nathalie Vergnolle
Received: 5 November 2009/Revised: 18 January 2010/Accepted: 15 February 2010/Published online: 26 March 2010
 The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract
Objective Our aim was to determine the contribution of
proteinase-activated receptor-2 (PAR2)-expressing bone
marrow-derived cells on the development of colonic
inﬂammation.
Materials Chimeric mice were generated by injecting
bone marrow cells from wildtype (PAR2
?/?) or PAR2
knockout mice (PAR2
-/-) into irradiated PAR2
?/? or
PAR2
-/- mice. Treatments: Colitis was induced by giving
2.5% dextran sodium sulfate (DSS) solution for 7 days or
by a single intracolonic administration of trinitrobenzene
sulphonic acid (TNBS, 2 mg dissolved in 40% ethanol).
Methods Seven days after the induction of colitis, bowel
thickness, inﬂammatory parameters [myeloperoxidase
(MPO) activity, macroscopic/microscopic damage scores],
and leukocyte trafﬁcking (visualized via intravital
microscopy) were assessed.
Results Total deﬁciency of PAR2 resulted in a marked
reduction in severity of both TNBS and DSS induced
colitis as assessed by MPO activity, macroscopic damage,
bowel thickness, and leukocyte adherence. Colitis was
attenuated in all chimeric lines in which there was loss of
PAR2 in the host, non-bone marrow-derived tissue, inde-
pendent of the status of PAR expression by bone marrow-
derived cells. Interestingly, TNBS colitis was attenuated in
PAR2
?/? chimeric mice with PAR2
-/- derived bone marrow
but these animals were not protected from DSS colitis.
Conclusions Expression of PAR2 by host-derived tissues
plays a dominant role in regulating colonic inﬂammation.
PAR2 expression by bone marrow-derived cells appears to
play a role in TNBS colitis but not in DSS induced injury.
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Introduction
Inﬂammatory bowel disease (IBD) including Crohn’s dis-
ease (CD) and ulcerative colitis (UC) are chronic
inﬂammatory conditions of the gastrointestinal tract. While
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DOI 10.1007/s00011-010-0181-9 Inﬂammation Researchthe exact etiology of IBD is unknown, genetic, environ-
mental and immunological factors are thought to be
involved [1, 2].
Several studies have suggested that proteases are
involved in the pathogenesis of intestinal inﬂammation in
IBD [3–8]. These proteases including thrombin, cathepsin
G, trypsin and tryptase can modulate inﬂammation by
cleaving and activating protease-activated receptors
(PARs) [9, 10]. PARs belong to the G-protein coupled
receptors (GPCR) family and are activated by a tethered
ligand, which is revealed upon proteolytic cleavage of the
N-terminus domain of PARs. Synthetic peptides, PAR-
activating peptide (PAR-AP), with sequence analogous to
the tethered ligand domain can activate PARs, in the
absence of proteolytic activity. Currently, four members of
the PAR family (PAR1 to PAR4) have been cloned and
characterized. In general, PAR1 is activated by thrombin;
PAR2 is activated by trypsin and mast cell tryptase; PAR3
is activated by thrombin; and PAR4 can be activated by
thrombin, trypsin, elastase, and cathepsin G [9]. Depending
on the cleavage site, activation of PARs can also be pre-
vented by proteases, through a ‘‘disarming’’ mechanism
[11–13].
In the gastrointestinal tract, different roles for PAR2
activation have been suggested. A strong expression for
PAR2 has been detected in different cell types, including
epithelial cells, neurons, ﬁbroblasts, inﬂammatory cells
[14–18]. Several studies have also highlighted PAR2 as an
important regulator of gastrointestinal functions including
secretion, ion transport, permeability, motility, and sensa-
tion [19–26]. Strong evidence suggests that PAR2 is a
critical mediator of colitis. In IBD patients, increased
expression of PAR2 and its potential activators (trypsin and
tryptase) have been observed [3, 8]. Studies have reported
that local administration of PAR2-AP induced acute
inﬂammatory response in the colon of mice [4, 27]. This
inﬂammatory response was characterized by increased
granulocyte inﬁltration, tissue damage/permeability and T
helper type 1 cytokines. Further investigation indicated that
PAR2-AP-induced colitis was in part mediated by the
activation of neuropeptide receptors, suggesting that PAR2
activation on sensory neurons could account for these pro-
inﬂammatory effects [5, 27]. However, PAR2 agonists are
also able to signal to endothelial cells and leukocytes, and
have been shown to provoke severe increase in leukocyte
rolling and adhesion [28]. On the other hand, systemically
administered PAR2-AP has been shown to exert anti-
inﬂammatory effects in an animal model of IBD induced
by trinitrobenzene sulphonic acid (TNBS) [7]. Therefore,
the exact role of PAR2 in the development of colitis was
uncertain and has been difﬁcult to identify, partly because
of the lack of selective PAR2 antagonists. Instead, a recent
genetic approach using PAR2-deﬁcient mice (PAR2
-/-) has
gained further knowledge, demonstrating that PAR2
-/-
mice were protected from developing colitis in three dif-
ferent models of IBD [TNBS, dextran sodium sulfate
(DSS), and oxazolone] [29]. The degree of leukocyte
trafﬁcking and the expression of various adhesion mole-
cules were signiﬁcantly reduced in PAR2
-/- mice upon
colitis. These results demonstrated that in IBD models, the
presence of functional PAR2 is able to control leukocyte
recruitment, exerting a pro-inﬂammatory role. However,
the cellular targets for PAR2 activation in the context of
IBD remained unknown, and the question of a direct
involvement of PAR2 activation on leukocytes for inﬂam-
matory cell recruitment during colitis was unsolved.
To further deﬁne the role of PAR2 in the regulation of
intestinal inﬂammation and homeostasis, we investigated
the impact of loss of PAR2 expression within bone marrow
derived cells and host or recipient tissues, by constructing
chimeric murine lines. Chimeric lines with normal, wild-
type expression of PAR2 or targeted deletion of PAR2 that
were reconstituted with PAR2
?/? or PAR2
-/- were assessed
in two differing models of colitis.
Materials and methods
Animals
Male or female PAR2-deﬁcient mice (PAR2
-/-) and wild-
type littermates (PAR2
?/?) were originally obtained from
Johnson & Johnson Pharmaceutical Research Institute
(Spring House, PA, USA), and bred at the University of
Calgary in a pathogen free and temperature controlled
environment. The mice were fed standard food pellets and
water ad libitum. All the experimental protocols were
approved by the Animal Care and Ethics Committee of the
University of Calgary and conducted in accordance to the
guidelines established by the Canadian Council on Animal
Care.
Bone marrow transplantation
Chimeric mice were generated as previously described
[30]. Brieﬂy, donor mice (PAR2
-/- or PAR2
?/?) were sac-
riﬁced via cervical dislocation and femurs and tibias were
isolated. Bone marrow cells from these bones were then
aspirated using a 1 ml syringe ﬁlled with RPMI media
(Invitrogen, Burlington, ON, Canada) under a sterile fume
hood. Female recipient mice (PAR2
-/- or PAR2
?/?,
4–6 weeks old) were irradiated with two radiation doses of
500 rads, 3 h a part, using a Gammacel 1000 (
137Cs source,
Nordion International, Kanata, ON, Canada). Immediately
after the second irradiation, recipient mice were injected
with 10 9 10
6 donor bone marrow cells through the tail
700 E. Hyun et al.vein. For the ﬁrst 2 weeks after the bone marrow cell
injection, chimeric mice were given neomycin sulfate
(0.2% wt/vol) solution as a drinking water. Chimeric mice
were allotted 8 weeks for bone marrow reconstitution.
Induction of colitis and study design
Colitis in chimeric mice was induced by TNBS or DSS as
previously described [29]. For TNBS-induced colitis,
chimeric mice were administered intracolonically with
100 ll of TNBS/ethanol solution (2 mg per mouse dis-
solved in 40% ethanol) via 1 ml syringe ﬁtted with a
catheter. During the administration of TNBS, mice were
lightly anaesthetized with halothane gas. For DSS-induced
colitis, chimeric mice were given 2.5% DSS solution
(2.5% wt/vol) as a drinking solution ad libitum for 7 days.
Colitis induced by TNBS or DSS was given 7 days to
develop.
The survival rate and body weight of chimeric animals
were measured daily after the induction of colitis. Seven
days after the induction of colitis, intravital microscopy
was performed on chimeric mice. After the last reading
from the intravital microscopy, chimeric mice were sacri-
ﬁced via cervical dislocation and bowel thickness as well
as inﬂammatory parameters [macroscopic/microscopic
damage scores, myeloperoxidase (MPO) activity] of the
colon were assessed. Bowel thickness was measured using
a digital caliper (Mitutoyo, Mississauga, Canada, resolu-
tion 0.01 mm).
Intravital microscopy
Intravital microscopy was performed on the distal colon of
chimeric mice in order to visualize changes in leukocyte
rolling/adherence and vessel diameter. Animals were
anaesthetized with a xylazine (10 mg/kg, MTC Pharma-
ceuticals,Cambridge,ON,Canada)andketamine(200 mg/kg,
Rogar/STB, London, ON, Canada) mixture. Mice were
also given 100 ll of ﬂuorescent dye, rhodamine 6G
(0.3 mg/kg, Sigma, St. Louise, MO, USA). The dose of
rhodamine 6G used in this study allows for visualization of
leukocyte/endothelium interaction while having no effects
on leukocyte kinetics [31, 32]. After mice were fully
anaesthetized, a midline abdominal incision was made
using a mono-polar cauterizer (Harvard apparatus, St.
Laurent, QC, Canada). Segments from the distal colon
were carefully exteriorized and placed on top of a viewing
pedestal. The exposed colon was superfused with bicar-
bonate-buffered saline (pH 7.4) throughout the experiment
to avoid tissue dehydration. Microcirculation was observed
using an inverted Olympus IX81 ﬂuorescent microscope
(Olympus, Melville, NY, USA) with 209 objective lens and
visualized by epi-illumination at 510–560 nm, using a
590 nm emission ﬁlter. After 15 min of equilibration per-
iod, single venules (20–40 lm in diameter) were selected
for the study.
The images of the selected venules were recorded for
5 min, which was considered as a basal reading. Additional
recordings were made for 5 min at 10 min intervals for
total of 80 min. The degree of leukocyte rolling, adherence
and vessel diameter were measured upon video playback.
Flux of rolling leukocytes was deﬁned as the number of
leukocytes per minute moving at a velocity less than
erythrocytes passing through a reference point in the ven-
ules. Leukocyte adherence was deﬁned as stationary
leukocytes on the endothelium (area of 100 lm vessel
length) for more than 30 s. The change in rolling leuko-
cytes and vessel diameter was calculated as the difference
between values at each interval to basal reading. Lastly,
parameters observed with intravital microscopy were
plotted along time of the observation and the area under the
curve was assessed.
Assessment of microscopic/macroscopic damage scores
After the intravital microscopy, colon samples from mice
were cut open along the mesenteric border and evaluated
for macroscopic damage as previously described. Param-
eters of macroscopic damage scores included edema,
hemorrhage, stricture formation, ulceration, fecal blood,
mucus, diarrhea, erythema, and adhesion. Each of the
parameters was given score of 1, if present, with excep-
tion of erythema and adhesion. Erythema was scored
based on length of the area being affected (0, if absent; 1,
if less than 1 cm; 2, if more than 1 cm). Adhesion was
scored based on severity (0, if absent; 1, for mild; 2, for
severe).
Microscopic damage scores were assessed on histolog-
ical colon samples from chimeric mice. Parameters of
microscopic damage scores included cellular inﬁltration,
submucosal edema, damage/necrosis, vasculitis, and per-
foration. Each of the parameters was scored based on
severity (0, if absent; 1, for mild; 2, for severe) with
exception to vasculitis and perforation, which were given
score of 1 if present.
Myeloperoxidase activity
MPO activity, an index of granulocyte inﬁltration, on colon
samples of chimeric mice was measured as previously
described [29]. Brieﬂy, colon samples were homogenized in
0.5% hexadecyltrimethylammonium bromide phosphate
buffer solution (pH 6.0). The homogenized colon samples
werethencentrifugedat13,0009gfor3 minandsupernatants
wereplacedon96 well plates. Buffer(200 ll)containing1%
hydrogen peroxide/O-dianisidine dihydrocholoride was
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wavelength of 450 nm for 1 min at 30 s interval using a
Spectromax Plus microplate spectrophotometer (Molecular
Devices, Sunnyvale, CA, USA) and SoftMax Pro software
(Molecular Devices).
Histology and chromosome Y staining
Colon samples from chimeric mice were ﬁxed in 10%
neutral buffered formalin and embedded in parafﬁn. Sec-
tions of 6 lm were cut with a Shandon Finesse 325
Microtome (Thermo Scientiﬁc, Middletown, VA, USA)
and mounted on a colorfrost microslide (VWR scientiﬁc,
Edmonton, AB, Canada).
For histology, tissue sections were stained with hema-
toxylin and eosin in accordance with classical methods of
histology. Representative photograph sections of each test
group were taken using a Retiga EXi camera (Q-imaging,
Surrey, BC, Canada) mounted on an Olympus IX81
microscope (Olympus, Melville, NY, USA) and obtained
using Volocity 3-D imaging software (Perkin Elmer,
Waltham, MA, USA).
Bone marrow reconstitution was assessed by detection
of the male (Y chromosome) cells in the female host via in
situ hybridization. In short, colonic tissue sections incu-
bated with a CY-3 tagged mouse chromosome Y probe,
according to the manufacturer’s instruction (Cambio Ltd,
Cambridge, UK). Cy3 signals from the slides were visu-
alized using a Fluoview FV1000 confocal microscope
(Olympus, Melville, NY, USA) and Olympus Fluoview
software.
Statistical analysis
Statistical comparisons among groups were performed
using a one-way analysis of variance followed by the
Student–Newman–Keuls test. Data were expressed as
mean ± standard deviation (SD), where a probability (p
value) of \0.05 was considered to be statistically signiﬁ-
cant. N number for each group
WT(WT) control = 8 (intrav = 8)
WT(KO) control = 9 (intrav = 8)
KO(WT) control = 7 (intrav = 7)
KO(KO) control = 7 (intrav = 7)
WT(WT) DSS = 14 (intrav = 9)
WT(KO) DSS = 11 (intrav = 8)
KO(WT) DSS = 16 (intrav = 9)
KO(KO) DSS = 14 (intrav = 8)
WT(WT) TNBS = 12 (intrav = 10)
WT(KO) TNBS = 12 (intrav = 11)
KO(WT) TNBS = 10 (intrav = 10)
KO(KO) TNBS = 15 (intrav = 15)
Results
Bone marrow reconstitution
Reconstitution of male bone marrow cells injected into
female irradiated mice was conﬁrmed by the detection of
chromosome Y-stained cells, detected in the colon of DSS-
treated chimeric mice (Fig. 1a). Chromosome Y staining
was present in all inﬁltrating inﬂammatory cells but absent
in the host derived epithelium, endothelium and enteric
neurons (Fig. 1a). As expected, no chromosome Y staining
was detected in female mice injected with female bone
marrow cells and challenged with DSS (Fig. 1b).
PAR2 expression by non-bone marrow-derived host
tissues, play a dominant role in regulating intestinal
inﬂammation in DSS colitis
Four chimeric mouse groups were referred to as WT(WT),
WT(KO), KO(KO), or KO(WT), where KO represent
PAR2
-/- and WT represent PAR2
?/?. The genotype inside
the bracket indicates the source of bone marrow cells and
genotype outside the bracket indicates the recipient mice.
DSS-induced colitis was characterized by loss in body
weight and increase in bowel thickness, MPO activity, and
damage scores, as compared to water (vehicle) consump-
tion (Fig. 2). DSS treatment led to a signiﬁcant loss of
body weight in all chimeric mouse groups, as compared to
their non-inﬂamed counterparts (Fig. 2a). However, DSS
treatment induced a larger loss in body weight in WT(WT)
mice, as compared to other chimeric mice groups, and that
effect was observed from day 4 until the end of the study
(Fig. 2a). The degree of increase in the bowel thickness
and MPO activity was signiﬁcantly reduced in KO(KO) or
KO(WT) mice, as compared to WT(WT) mice (Fig. 2b, c).
Fig. 1 Chromosome Y staining in colon samples from DSS treated
chimeric mice (a, b). Sections of colon from chimeric mice were
hybridized with a CY-3 tagged DNA probe for mouse chromosome
Y. Female PAR2
?/? mice were injected with either male (a) or female
(b) PAR2
?/? bone marrow cells. Colitis was induced by giving
chimeric mice 2.5% DSS as a drinking solution for 7 days. Scale bar
100 lm. PAR Protease-activated receptor, DSS dextran sodium
sulfate
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distal colon of mice, characterized by tissue edema, fecal
blood, and erythema. Both KO(KO) and KO(WT) mice
showed signiﬁcantly reduced macroscopic damage scores
(Fig. 2d). Signs of microscopic damage were also observed
with DSS treatment, which were characterized by submu-
cosal edema, damage/necrosis of the epithelium and
cellular inﬁltration (Fig. 2e). No signiﬁcant difference was
observed between chimeric mouse groups in terms of
microscopic damage scores. Interestingly, while most
inﬂammatory parameters (bowel thickness, MPO, macro-
scopic damage score) were reduced in chimeric PAR2
-/-
mice, whether they express or not PAR2 on bone marrow
cells, these parameters were not reduced in mice that did
not express PAR2 on bone marrow-derived cells, but
express the receptor on other recipient tissues [WT(KO)
mice] (Fig. 2). This result shows that in the DSS model,
PAR2 deﬁciency only on bone marrow-derived cells is not
sufﬁcient to reduce efﬁciently inﬂammatory signs in the
colon.
Fig. 2 The effects of 2.5% DSS-induced colitis on changes in body
weight (a), bowel thickness (b), myeloperoxidase (MPO) activity (c),
macroscopic and microscopic damage scores (d, e, respectively) in
chimeric mice. Seven days following DSS treatment, colonic tissues
from chimeric mice were harvested. Chimeric mice were generated by
injecting bone marrow cells from either PAR2
?/? or PAR2
-/- mice
(indicated as WT or KO, respectively) into irradiated recipient mice.
Four chimeric mice were used; WT(WT), WT(KO), KO(KO), or
KO(WT) (groups of 8–10 mice), where the genotype inside the bracket
indicatesthesourceofbonemarrowcells.
OSigniﬁcantlydifferentfrom
the control (non-inﬂamed) group, *signiﬁcantly different from WT
(WT) group treated with DSS,
#signiﬁcantly different from KO(KO)
group treated with DSS (P\0.05).Values are shown asmean ± stan-
dard deviation (n = 7–16). DSS dextran sodium sulfate
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is reduced in chimeric PAR2
-/- mice irrespective of the
origin of donor bone marrow cells
Intravital microscopy was performed in order to assess
changes in ﬂux of rolling leukocytes and adherent leuko-
cytes along the colonic venules of the chimeric mice. DSS
treatment induced a signiﬁcant increase of the area under
the curve for the ﬂux of rolling leukocytes and leukocyte
adherence in all of the chimeric mice groups as compared
to non-inﬂamed counterparts (Fig. 3). However, DSS-
induced increase in rolling and adhesion were signiﬁcantly
reduced in both KO(KO) and KO(WT) mice as compared
to WT(WT) mice (Fig. 3). No statistical signiﬁcance was
observed between WT(WT) and WT(KO) for the area
under curve for leukocyte rolling and adherence. These
results show that in the DSS model, the lack of PAR2
expression on bone marrow-derived cells is not sufﬁcient to
reduce leukocyte trafﬁcking parameters (rolling and adhe-
sion), but PAR2 deﬁciency on recipient tissues other than
bone marrow cells is necessary to modulate leukocyte
trafﬁcking.
Transplantation of bone marrow cells from donor
PAR2
-/- mice confers protection from TNBS-induced
colitis
As was noted in the DSS model, TNBS-induced colitis led
to loss in body weight in chimeric mice (Fig. 4a). However,
two groups of mice: KO(KO) and WT(KO) lost signiﬁ-
cantly less body weight as compared to WT(WT) mice from
day 2 until the end of the study. For KO(WT) mice, they
also lost signiﬁcantly less body weight than WT(WT) mice,
but only at two time-points (days 2 and 4), and for all time-
points this group showed signiﬁcantly higher weight loss
compared to KO(KO) mice (Fig. 4a). Interestingly, after
TNBS challenge, KO(KO), KO(WT), and WT(KO) all
showed signiﬁcantly reduced bowel thickness and MPO
activity as compared to WT(WT) mice (Fig. 4b, c). Inhi-
bition of those inﬂammatory parameters in WT(KO) mice
though, was not as profound as in PAR2-deﬁcient mice
reconstituted with either PAR2-expressing or PAR2-deﬁ-
cient bone marrow cells (KO(WT) or KO(KO) groups,
respectively) (Fig. 4a–c). TNBS-induced colitis also
induced a signiﬁcant increase in tissue adhesion, edema and
erythema, which contributed to the increase in macroscopic
damage score in WT(WT) mice (Fig. 4d). KO(KO),
KO(WT) and WT(KO) mice challenged with TNBS simi-
larly showed reduced macroscopic damage scores as
compared to WT(WT) mice. As for microscopic scores
induced by TNBS instillation, only KO(KO) mice showed a
signiﬁcant reduction compared to WT(WT) mice (Fig. 4).
In summary, these studies reveal that expression of
PAR2 by either bone marrow-derived cells or recipient
tissues is pro-inﬂammatory in the TNBS model of colitis.
Transplantation of bone marrow cells from donor
PAR2
-/- mice reduces leukocyte adherence in TNBS-
induced colitis
Leukocyte rolling and adherence along the colonic venules
after the development of TNBS-induced colitis was also
assessed using intravital microscopy. TNBS challenge
signiﬁcantly increased the area under the curve for the ﬂux
of rolling leukocytes in all groups of mice, and none of the
different chimera was able to modulate TNBS-induced
leukocyte rolling (Fig. 5a). However, leukocyte adherence
along the colonic venules was signiﬁcantly reduced in
KO(KO), KO(WT), and WT(KO) mice as compared to
WT(WT) mice (Fig. 5b). These studies reveal that PAR2
expression by either bone marrow-derived cells or recipient
tissues regulates leukocyte adhesion and this may represent
Fig. 3 Changes in ﬂux of rolling leukocytes (a) and adherent
leukocytes (b) along the colonic venules of chimeric mice. Mice
were treated with 2.5% DSS or vehicle (water) for 7 days and
intravital microscopy was performed. Chimeric mice are designated
as indicated in Fig. 2.
OSigniﬁcantly different from the control (non-
inﬂamed) group, *signiﬁcantly different from WT(WT) group treated
with DSS,
#signiﬁcantly different from KO(KO) group treated with
DSS,
$signiﬁcantly different from WT(KO) non-inﬂamed group
(P\0.05).Valuesareshownasmean ± standarddeviation(n = 7–9).
AUC Area under the curve, DSS dextran sodium sulfate
704 E. Hyun et al.a critical mechanism accounting for the pro-inﬂammatory
actions of PAR2 in colitis.
Discussion
Since the discovery of a role for PAR2 in inﬂammation [28,
33] and the induction or inhibition of inﬂammatory signs in
response to PAR2 agonists [7, 10, 34, 35], there have been
controversies over its role as a pro- or an anti-inﬂammatory
message, depending on the cell types that were activated.
The studies outlined here provide evidence that PAR2
activation is a pro-inﬂammatory signal in the context of
animal models of IBD, and provide further understanding
on the source of PAR2-expressing cells that are playing or
not a critical role in colitis. We showed here that deﬁciency
Fig. 4 The effects of TNBS-induced colitis (2 mg in 40% ethanol)
on bowel thickness (a), degree of weight loss (b), myeloperoxidase
(MPO) activity (c), macroscopic and microscopic damage scores (d)
in chimeric mice. Colon tissues were processed for histology 7 days
following treatment with TNBS and microscopic damage was
assessed. Chimeric mice are designated as indicated in Fig. 2.
*Signiﬁcantly different from the WT(WT) group treated with TNBS,
#signiﬁcantly different from the KO(KO) group treated with TNBS
(P\0.05). Values are shown as mean ± standard deviation
(n = 10–15). TNBS trinitrobenzene sulphonic acid
Fig. 5 Changes in ﬂux of rolling leukocytes (a) and adherent
leukocytes (b) along the colonic venules of chimeric mice. Mice
were injected with TNBS (2 mg in 40% ethanol) intrarectally and
intravital microscopy was performed 7 days thereafter. Chimeric
mice are designated as indicated in Fig. 2. *Signiﬁcantly different
from WT(WT) group treated with TNBS (P\0.05). Values are
shown as mean ± standard deviation (n = 10–15). AUC Area under
the curve, TNBS trinitrobenzene sulphonic acid
Bone marrow-derived PAR2 in colitis 705of PAR2 expression on bone marrow-derived cells was not
sufﬁcient to protect from DSS colitis, although it seemed
sufﬁcient in the other model of IBD: the TNBS model.
However, PAR2-deﬁciency on recipient tissues other than
bone marrow-derived cells was sufﬁcient in all models to
induce strong resistance to the development of colitis.
While the mechanisms that underlie the pro-inﬂammatory
effects of PAR2 activation seemed to involve leukocyte
recruitment, PAR2 activation on tissue resident cells rather
than leukocytes seemed to play the most critical role in
colitis.
PAR2 is widely expressed in almost all cell types present
in the gut, including endothelium, epithelium, enteric
neurons, ﬁbroblasts, smooth muscle cells, and immune
cells [14–17]. Various in vitro studies have shown that
the activation of PAR2 in these cells may interplay with the
inﬂammatory process. Studies have indicated that the
activation of PAR2 promotes the release of pro-inﬂamma-
tory cytokines and recruitment of immune cells [36–41],
but can also protect from inﬂammatory insults, through the
release by epithelial cells of prostaglandins or neuropep-
tides by primary afferents. Because the expression of PAR2
is changed in tissues from IBD patients, the idea that PAR2
could contribute to the pathogenesis of the disease has been
evoked [42–46]. However, which cellular source for PAR2
expression plays a central role in colitis, and whether this
role is pro- or anti-inﬂammatory depending on the cell
types, were still open questions. We focused our attention
on the expression of PAR2 on bone marrow-derived cells,
as a major role for PAR2 activation on leukocyte recruit-
ment has been suggested by many studies [28, 34, 40, 47].
PAR2
-/- chimeric mice were protected from DSS-induced
colitis, irrespective of the source of bone marrow cells.
Thus, in DSS challenge, PAR2 expressed on the recipient
tissues appears to play a major role in the development of
colitis. In TNBS challenge also, we observed that PAR2
-/-
chimeric mice were protected from developing colitis
irrespective of the source of bone marrow cells. We also
observed that PAR2
-/- bone marrow cells conferred pro-
tection in PAR2
?/? mice challenged with TNBS. Thus, in
the TNBS model, PAR2 expressed on both recipient and
bone marrow derived cells appears to play a major role in
the development of colitis. Different mechanisms involved
in the initiation and maintenance of the inﬂammatory
response in these two models may be responsible for these
differences. The current concept of pathogenic mechanism
of TNBS involves the binding of TNBS to colonic or
microbial proteins to generate hapten–protein complex.
This complex is then thought to be recognized by the
immune system mainly involving macrophages and T cells
that induce inﬂammatory response [48, 49]. In contrast, the
pro-inﬂammatory effects of DSS is generally thought to be
initiated by its cytotoxic effects on the colonic epithelial
cells, and therefore loss of epithelial barrier integrity,
which leads to an increased exposure of the innate immune
system to bacteria and their proteins [49, 50]. The pro-
inﬂammatory signal thereby initiated leads to the recruit-
ment of leukocytes, mainly neutrophils [49, 51]. Thus,
epithelial cell response is generally more extensive for the
pathogenic mechanism of DSS- rather than TNBS-induced
colitis. The results of the present study could suggest that
PAR2 activation plays a severe pro-inﬂammatory role in
the response of intestinal epithelial cells to DSS injury.
Indeed, previous studies have shown that PAR2 activation
on intestinal epithelial cells can promote the release of IL-8,
a potent chemotactic factor for immune cells (especially
neutrophils) [41], and increased intestinal epithelial cell
permeability [19]. Considering this evidence, the impor-
tance of PAR2 on the recipient tissues during the
development of DSS-induced colitis may be due, at least in
part, to its presence in intestinal epithelial cells. Our results
suggest also that PAR2 activation on epithelial cells is a
crucial and necessary event to the development of DSS
colitis. However, it is also important to point out that
PAR2
-/--recipient mice were protected from the develop-
ment of colitis in both models: DSS and TNBS. TNBS-
induced colitis also strongly depends on the loss of
epithelial barrier functions, and on the presentation to the
innate immune system of luminal microbial antigens, as it
has been well established that TNBS colitis did not develop
in the absence of colonic ﬂora [52]. The activation of PAR2
on intestinal epithelial cells could also be a crucial event of
TNBS-induced colitis. However, our results also show that
PAR2 activation on bone marrow-derived cells is a step
limiting the event of TNBS colitis. In transmural inﬂam-
matory damage such as the ones observed in the TNBS
colitis model and that are common in that way to CD
characteristics, regulation of PAR2 activation speciﬁcally
on bone marrow cells may therefore represent a potential
novel form of therapy.
In this study, we have demonstrated a strong correlation
between reduction in inﬂammatory response and a reduc-
tion in leukocyte adherence/MPO activity. The process of
leukocyte adherence is mainly mediated through interac-
tion between adhesion molecules expressed on the
endothelium (intracellular adhesion molecule, ICAM-1, or
vascular cell adhesion molecule, VCAM-1) and leukocytes
(integrins; composed of alpha and beta subunits) [53, 54].
Previous studies have shown adhesion molecules to
mediate the development of colitis. In DSS-induced colitis,
antibodies against various adhesion molecules (E-selectin,
MAdCAM-1, VCAM-1, and ICAM-1) have been shown to
attenuate the intestinal inﬂammatory responses in animals
[32, 55, 56]. In TNBS-induced colitis, antibodies (anti-
VCAM-1 or anti-MAC-1) or leukocytes (anti-MAC-1)
have been shown to decrease tissue damage and monocyte
706 E. Hyun et al.inﬁltration [57, 58]. We and others have also shown that
PAR2 plays an important role in up-regulating the
expression of adhesion molecules including VCAM-1 and
ICAM-1 in inﬂammatory conditions [29, 38, 59]. Of par-
ticular note, these adhesion molecules (with the exception
of MAC-1) are commonly found on endothelial cells,
which could suggest that PAR2 activation on this cell type
constitutes the major signal for leukocyte recruitment.
PAR2 activation on endothelial cells has been shown to
promote the release of IL-8 and increase the expression of
various adhesion molecules [36, 38, 60]. PAR2 activation
on endothelial cells therefore appears as a potential major
player to promote leukocyte recruitment upon colitis.
Over recent years, the prospect of using bone marrow
transplant as therapy for IBD has been gaining attention.
Several case studies have shown improved clinical scores
and prolonged periods of remission in IBD patients fol-
lowing autologous bone marrow transplant [61, 62]. The
results of our study showed that in both the DSS and TNBS
models of colitis, cells derived from recipient may play a
greater role in the regulation of intestinal inﬂammation and
tissue damage. Thus, beneﬁcial effects of bone marrow
transplant may not be related to the re-setting of PAR2
functions in the patients that were successfully treated by
bone marrow transplant.
In summary, PAR2 expressed on cells derived from the
recipient rather than bone marrow-derived cells appears to
play a prominent pro-inﬂammatory role in experimental
models of IBD. There are numerous possible cell types
derived from the recipient that may contribute to the
development of colitis including epithelial and endothelial
cells. There has been a long debate on whether the main
effects of PAR2 in leukocyte recruitment processes are due
to the activation of the receptor on endothelial cells or
leukocytes. This study clearly shows that in both models
(DSS and TNBS), expression of PAR2 on cells other than
bone marrow-derived plays a critical role in colitis devel-
opment and leukocyte recruitment. A partial role to PAR2
expression on bone marrow-derived cells could only be
attributed in the context of TNBS colitis, but did not detract
from the role of PAR2 on other cell types.
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